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Purpose: Low-intensity continuous ultrasound (LICUS) is an emerging high-dosimetry
ultrasound-based therapy for accelerated tissue healing and the treatment of myofascial
pain. In this study, LICUS treatment is clinically evaluated for chronic upper neck and
shoulder pain in a randomized, multi-site, double-blind, placebo-controlled study.
Patients and Methods: CONSORT guidelines were followed in conducting and reporting the clinical trial. Thirty-three participants with upper trapezius myofascial pain were
randomized for treatment with active (n=25) or placebo (n=8) devices. Investigators and
subjects were blinded to treatment groups. Participants self-reported pain daily, rating
from 0–10 on the numeric rating scale. If pain rating was more signiﬁcant than or equal
to 3, the LICUS (3MHz, 0.132W/cm2, 1.3W, 4 hours) was self-applied for total energy
dosimetry of 18,720 Joules per treatment. During the 4-week study, daily pain rating was
recorded. If LICUS treatment was delivered, pain before, during, and after treatment
were recorded as well as the global rate of change (GROC). Independent t-tests were
used to assess change from baseline and differences between treatment groups.
ClinicalTrials.gov: NCT02135094.
Results: There was a 100% completion rate for participants enrolled in the study and no
signiﬁcant differences between the groups regarding demographic variables or baseline
outcome measures. Participants treated with active therapy observed a signiﬁcant mean
pain reduction from baseline of 2.61 points for active (p<0.001), compared to 1.58 points
decrease from baseline for placebo (p=0.087), resulting in a 1.03 points signiﬁcant
decrease in the active group over placebo (p=0.003). The total GROC was signiﬁcantly
higher in the active group at 2.84 points compared to the placebo group at 0.46 points
(p<0.001).
Conclusion: Low-intensity continuous ultrasound treatment signiﬁcantly reduced pain in
patients with upper trapezius myofascial pain of the neck and shoulder. LICUS treatment
showed a clinically meaningful improvement in the GROC scores for patients. The
results from this clinical trial indicate that the LICUS treatment of 18,720 Joules can
effectively be used to treat clinical pain related to upper trapezius myofascial pain.
Further research could investigate varying dosimetry to improve efﬁcacy and/or reduce
the dose.
Keywords: sustained acoustic medicine, myofascial trigger points, non-steroidal antiinﬂammatory drugs, NSAIDs, non-invasive therapy, soft tissue healing, chronic musculoskeletal
pain
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Background
Neck and back pain is the most common musculoskeletal
condition, affecting over 84% of the adult population.1,2
Back pain costs the United States healthcare system over
$100 billion annually,3–6 and there are several etiologies of
back pain including anatomic, nerve root, muscle, myofascial structure, bone, joint, intervertebral disc, and organ
abnormalities or injury.6 Myofascial trigger points,
a common occurrence in those with back pain, have been
described as discrete hypersensitive areas presenting in
taut bands of muscle.7–10 Myofascial trigger points are
classiﬁed as active or latent. Active myofascial trigger
points produce local and referred pain when compressed,
among other clinical symptoms, such as limiting full muscle lengthening and muscle weakening.7,11 Latent myofascial trigger points are painful only when palpated and do
not present with as great of mechanical response as active
myofascial trigger points.8,12
Myofascial trigger points are often treated non-invasively
with ischemic compression, laser therapy, and ultrasound
treatment.13 Ischemic compression is applied with enough
manual pressure to produce skin blanching in the treatment
area and can result in a reduction in pain score.14 Laser
therapy studies have shown conﬂicting results in the treatment of myofascial trigger points, which could be attributed
to the range of parameters used in the treatment and limited
depth of penetration.15 Low-intensity ultrasound produces
mechanobiological effects stimulating cellular and tissue
mechanisms treating multiple conditions, including myofascial trigger points,16–19 back pain,20,21 tendinopathy,22,23 and
joint arthritis pain.24–26 The inconsistency of ultrasound
treatment effectiveness cited in the literature and metanalysis
can be attributed to a lack of optimization of ultrasound duty
cycle, frequency, intensity, and power as well as patient
compliance.27–29
Over the last decade, research suggests daily increased
energy deposition via low-intensity ultrasound can improve
patients’ quality of life. Low-intensity continuous ultrasound
(LICUS) devices enable patients to self-apply non-invasive
therapeutic ultrasound for up to four hours per day, increasing total energy deposition to almost 20,000 Joules compared
to an ON/OFF 10 to 20-minute therapist applied ultrasound
treatment, which typically involves 700 to 2,000 Joules of
energy deposition once a week.30,31 Research into lowintensity continuous ultrasound for musculoskeletal injuries
and disorders focuses on daily applied LICUS. Self-applied
wearable LICUS devices enable longer treatment durations,
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increasing energy deposition,22 and accelerate healing.22,31,32
LICUS produces ultrasound without pulses and increases
muscle temperature,33,34 creating a potential for increased
blood ﬂow,35 increased connective tissue extensibility,36,37
altered nerve conduction velocity,38 and with less probability
of forming adverse standing waves leading to potential tissue
damage. Recent literature reviews on LICUS have found the
treatment is effective in decreasing pain and improving function in musculoskeletal injuries.29
Additionally, ultrasound can have mechanical and biologically driven effects such as myoregeneration,32 improve
biomechanics,31
anti-inﬂammatory,39
and
thermal
33,34
effects.
The objective of this study was to determine
the effectiveness of daily 4-hour LICUS at alleviating upper
trapezius active myofascial pain and muscle tenderness
over a 4-week treatment period. We hypothesized that
4-hours of LICUS treatment of upper neck and back trigger
point pain would provide additional pain reduction over
only 1-hour of LICUS treatment by Lewis et al (2013).19
The study and methods followed the Consolidated
Standards of Reporting Trials (CONSORT)40

Methods
A multi-site, randomized, double-blind placebo-controlled
trial design was used to direct this study. The 4-week study
design and 4-hour LICUS treatment protocol was chosen to
build off of the results of Lewis et al (2013),19 and determine
potential increased pain reduction due to the longer (+3 hour)
LICUS treatment. For the primary outcome measure, change
in pain on the numeric rating scale 0–10 (NRS) after LICUS
treatment, participants were recruited on a 3:1 basis to active
and placebo, based on statistical power analysis from Lewis
et al (2013) 1 hour of LICUS treatment for trapezius muscle
spasm pain. Using the mean LICUS pain reduction for the
ﬁrst 2 days of the study (active mean 21.25% ± 9%, placebo
mean 4% ± 9%), and mean pain reduction for the entire 10
days of the study (active mean 16% ± 7%, placebo 8% ± 7%)
from Lewis et al (2013); A sample size of 24:8 active to
placebo provided over 95% power and 80% power for the
primary outcome measure NRS pain reduction. We also
anticipated a stronger active treatment effect size for pain
reduction in our study since LICUS was to be applied for
4-hours per treatment versus only 1-hour per treatment in
Lewis et al (2013).19 Total participants enrolled and randomly assigned to an active (n = 25) or placebo (n = 8)
treatment group was slightly above target (+1 active).
Randomization occurred by participants drawing numbers
out of a hat that matched the serial numbers of the unknown
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device set-up (either active or placebo). The active ultrasound group sample size was powered based on a previous
study on LICUS for upper back pain using self-reported pain
scales. Adequate placebo was used for comparison.The participants, investigators, and biostatistician were blinded to
treatment group assignments.

Participants
Thirty-three participants (12 males and 21 females, age =
33.3 ± 13.3 y, height = 169.6 ± 11.4 cm, mass = 74.4 ±
15.0 kg) were recruited from the patient population at the
enrolment sites. All patients enrolled completed the study
(Table 1). Participants were recruited and screened per the
diagnostic criteria. All participants provided written
informed consent prior to enrolling in the study, which
was approved by the Institutional Review Board for
Human Subjects for Brigham Young University and the
study was conducted in accordance with the Declaration of
Helsinki.41 Participants were included if they were
between the ages of 18–65 y and were diagnosed with
upper trapezius trigger points by a health care practitioner.
The health care practitioner (physician or athletic trainer)
diagnosed the participant with pain caused by trapezius
myofascial trigger point if they presented with a palpable
taut band, with pain greater or equal to 3.0 out of 10 on
a numeric rating scale (NRS) at least 3 times per week and
subjectively reported stiffness and/or restricted range of
motion in the upper trapezius. Participants were excluded
if they were not willing to follow the protocol and followup procedures, had a known neuropathy, were type I or
type II diabetic, had surgery in the target area within the
past 6 months or had other contraindicated conditions to
therapeutic ultrasound. If applicable, participants were
asked to discontinue the use of pain medications and
topical analgesic creams or gels and discontinue massage
therapy or spinal manipulation treatments. This was conﬁrmed by asking participants if they had used any
Table 1 Patient Demographics
Patient Demographic Data
Variable

Active

Placebo

Ultrasound

Ultrasound

N
Sex (M/F)

25
9/16

8
3/5

0.999

Age, years

34.2 ± 13.9

30.3 ± 10.9

0.415

Height
Weight

169.8 ± 12.1
75.1 ± 13.1

169.1 ± 9.7
72.2 ± 22.4

0.869
0.737
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treatment other than the LICUS in their daily diaries.
The study started in June 2014 and was completed by
September 2015 (Clinical trial: NCT02135094).

Procedures
Enrolled participants provided demographic and baseline
information during their initial visits to the enrollment site.
Outcomes measures included: 1) pain rated on a 10-point
numeric rating scale (NRS), 2) participant’s overall feeling
rated on a 15-point global rate of change (GROC) scale.
Baseline measurements were taken on Day 1, and then
participants were assigned an active or placebo LICUS
device based on their group assignment.
A daily diary was given to the participants, which
contained the NRS pain scale and GROC scale questions.
Participants were instructed to ﬁll out the daily dairies
after treatment, and the diaries were checked for compliance at the 2-week follow-up visits. Participants were
instructed only to apply the device if the daily pain rating
was greater than or equal to 3/10. Participants made a total
of 3 visits to the enrollment site, once at baseline and then
at 2-week intervals for 4 weeks. At the week-2 and week-4
visits, the same procedures were used as the initial visit.
The study was completed after the 4-week visit, and no
further follow-up was conducted (Figure 1).

LICUS Device Treatment Protocols and
Placement
Following device use protocol from the manufacturer’s
training, the investigator aided the participant in applying
the device the ﬁrst time. If participants presented with
a unilateral trigger point, they placed one transducer over
the trigger point of the trapezius muscle on that side. If
participants had bilateral trigger points, they were
instructed to place one transducer over each trigger point
(total of two transducers). Participants placed the transducer over the most painful trigger point if more than one
unilateral trigger point was reported. The bilateral application of the LICUS device over the upper trapezius is
demonstrated in Figure 2. Participants were instructed to
wear the device for 4 hours each time they applied it.

P-value

Numeric Rating Scale
The primary outcome measure of the study was pain
reduction from LICUS treatment. Participants recorded
their NRS score daily for the 4-week clinical trial. The
NRS is a validated and consistent measurement of pain for
several musculoskeletal conditions, including chronic

submit your manuscript | www.dovepress.com

DovePress

1279

Dovepress

Petterson et al

Enrollment

Assessed for eligibility (n= 38)
Excluded (n=5)
♦ Protocol burden (n=4)
♦ Neuropathy (n=1)
♦ Type 1 or type diabetes (n=0)
♦ Upper shoulder surgery in 6 months (n=0)

Ultrasound Intervention
Daily Measurements: Pain
Measurements on device use:

Pain (30 min, 2 hours, 4 hours)
GROC

Randomized (n= 33)

Allocation
Placebo (n= 8)

Allocated to intervention (n= 25)
♦ Received allocated intervention (n= 25)

Follow-Up
Lost to follow-up (give reasons) (n=0 )
Week - 2

Lost to follow-up (give reasons) (n= 0)
Week - 2

Analysis
Analysed (n= 25 ) – Week 4
♦ Excluded from analysis (n= 0 )

Analysed (n=8 ) – Week 4
♦ Excluded from analysis (n=0 )

Figure 1 The study schematic. Patients were enrolled and evaluated for baseline pain scores on day one of the studies. Two- and four-week follow-ups were included to
evaluate compliance.

has been reported as a signiﬁcant minimal clinically
important difference for chronic musculoskeletal pain.44

Global Rating of Change Scale

Figure 2 Wearable long duration ultrasound device (SAM®, ZetrOZ Systems LLC,
Trumbull, CT) bilateral placement. If patients were experiencing bilateral trigger
points, a transducer was placed on each side over the trigger point. If the patient
experienced unilateral trigger points, only one transducer was used. The transducer
was placed over the most painful trigger point if the patient was experiencing
multiple trigger points on one side.

myofascial trapezius pain.42–44 If the participant’s daily
NRS score was greater or equal to a 3/10, the participant
was instructed to apply the assigned LICUS device, active
or placebo. The participants were asked to record the NRS
during the treatment at 30m, 120m, and immediately after
the LICUS treatment. A reduction in 1 point on the NRS
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The secondary outcome measure of the study was GROC
improvement when LICUS was applied. On days participants wore the assigned device; they were instructed to
record their GROC score after the treatment. The GROC
scale assesses a participant’s overall improvement or deterioration during a treatment intervention period.45–48, The
“global” aspect of the scale allows participants to consider
what is important to them when completing the measurement. Participants responded on a 15-point GROC scale to
the following question,48–50 “Consider how your body feels
overall right now compared to yesterday and circle the number that describes how you feel.” The 15-point scale was
labelled with −7 being “a very great deal worse,” 0 being “no
change,” and +7 being “a very great deal better.” GROC was
not assessed at baseline because it was only measured after
treatments were administered to determine the participants’
global feeling compared to the previous treatment.
GROC scales have high test-retest reliability (ICC =
0.90) in patients with low back pain.49 GROC scales have
also been shown to have good face validity.46,49 We used
a 15-point scale,50 but the minimal detectable change and
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minimal clinically important difference using an 11-point
scale are 0.45 points and 2 points,19,49,50 respectively. The
minimal detectable change and minimal clinically important difference have not been reported for a 15-point scale.

LICUS Device
A LICUS device (SAM®, ZetrOZ Systems, LLC., Trumbull,
CT) was used for this study. The device delivers pre-set lowintensity continuous ultrasound at 3 MHz frequency and 0.132
W/cm2 spatial average temporal average intensity (ISATA). The
device has single or dual transducer modes and has been FDA
approved for home use to wear for up to 4 hours of daily use
and deliver 18,720 Joules per treatment (dual transducer).
The LICUS device was self-applied by the participant and
operated for the full 4-hour/18,720 Joule treatment. It is easy
to use the device with 2 buttons - an on/off button in the middle
of the device and a time button on the side of the device. All
participants were instructed to press the time button up to 4
hours. The placebo devices supplied for the study had the
power wire to the transducer cut by the manufacturer, resulting
in no ultrasound energy being produced, but the power to the
on/off and time setting lights on the device would remain to
function as normal. No alternative instructions were given to
the placebo or active treatment group since the device functioned the same for both groups, and the ultrasound intensity
was too low to produce a signiﬁcant sensation.

Data Analysis
Baseline demographic and outcome variable data were
compared between treatment groups using independent
t-tests to assess adequate randomization.51–53 Chi-squared
was used to assess the sex proportion difference between
groups. Independent t-tests were used to assess NRS pain
scores and GROC change from baseline and difference
between active and placebo groups.53

Results
Enrollment and Participants
Demographics
Thirty-eight (38) participants were screened, and thirtythree (33) subsequently enrolled in the study (Figure 1).
Participants were randomized into active (n = 25) or placebo (n = 8) groups. There were no differences in demographics between groups (Table 1). Overall, averages were
(± standard deviation): height 169.6 cm (±11.4 cm),
weight 74.1 kg (±15.0 kg), age 33.3 years (±13.3 years).

Journal of Pain Research 2020:13
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All participants completed the 4-week study with 100%
compliance and no adverse events.

Device Use
On average, the active group used the device 2.77 ± 0.476
times per week, while the placebo group used the device
3.2 ± 0.752 times per week. The difference between the
groups was not signiﬁcant (p=0.8, independent t-test)

Pain Change from Baseline
Pain before the intervention was assessed at baseline
(day 1), then daily before each treatment during the intervention period of 4 weeks. Post-treatment pain scores were
used to evaluate change from baseline. The active group
showed a signiﬁcant decrease in pain from baseline as
early as the 1st week and persisted through the 4-week
study (p<0.001, independent t-tests of week average compared to baseline) (Table 2). The placebo group did not
show a signiﬁcant difference; however, a trend toward
a decrease in pain was noticed at week 3 and week 4
compared to baseline (p=0.070 and p=0.087, respectively).
While this could indicate a placebo effect, the difference
between groups for change from baseline was signiﬁcant
for all 4 weeks assessed (p<0.001 for weeks 1–3, p=0.003
for week 4), showing a more signiﬁcant change from
baseline for the active LICUS group compared to placebo.

Pain Change During the Treatment
Session
The pain level was assessed daily and averaged to group pretreatment scores (Table 3). When LICUS devices were applied
(NRS score ≥ 3), the NRS pain score was reported at 30
minutes into the treatment, 2 hours into treatment, and 4
hours (post-treatment). The active group showed
a signiﬁcant decrease in pain as early as 30 minutes (−0.416
points, p<0.001), and this pain reduction became greater
through the 4-hour treatment compared to pre-treatment pain
(−2.16 difference, p<0.001). The placebo group did not show
a difference at 30 minutes into treatment compared to pretreatment but did show a signiﬁcant decrease in pain after 2
hours and post-treatment. Pain reduction in the placebo group
was less than 1.0 minimal clinically important difference for
NRS pain scores.44 The pain reduction for the active group
was signiﬁcantly greater compared to pain reduction observed
in the placebo group at 30 minutes (−0.179 points, p=0.008), 2
hours (−0.747 points, p<0.001), and 4 hours (−1.28 points,
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Table 2 Primary Outcomes. The Pain Reported at Baseline and Weekly Averages. Change in Pain from Baseline and
Comparison Between Groups Evaluated Using Independent t-tests
Pain Diary Data (NRS)
Time

Active

Placebo

Between Group Mean 95% CI

P-value

Baseline
Week 1

5.60 ±1.58
3.54 ±1.64

5.44 ±1.95
4.58 ±2.20

0.163 (−1.22 to 1.55)
−1.03 (−1.65 to −0.42)

0.81
0.001

Week 2

3.26 ±1.58

4.74 ±2.39

−1.48 (−2.12 to −0.84)

<0.001

Week 3
Week 4

3.09 ±1.54
2.98 ±1.62

3.92 ±2.10
3.86 ±2.30

−0.827 (−1.46 to −0.19)
−0.87 (−1.64 to −0.106)

0.011
0.026

−2.05 ±1.64

−0.860 ±2.21

−1.20 (−1.76 to −0.631)

0.001

−2.76 to −1.35
p<0.001

−2.53 to 0.81
p=0.306

−2.34 ±1.59
−3.03 to −1.65

−0.693 ±2.38
−2.49 to 1.11

−1.65 (−2.23 to −1.06)

<0.001

p<0.001

p=0.443

−2.51 ±1.55

−1.52 ±2.11

−0.989 (−1.57 to −0.410)

<0.001

−3.18 to −1.83

−3.14 to 0.110

p<0.001

p=0.07

−2.61 ±1.63
−3.34 to −1.90

−1.58 ±2.30
−3.40 to 0.24

−1.03 (−1.71 to −0.358)

0.003

p<0.001

p=0.087

NRS mean change from baseline 95% CI
Week 1

Week 2

Week 3

Week 4

Table 3 The Pain Reported Before, 30 Minutes into the Treatment, 2 Hours into Treatment, and Post-Treatment (4
Hours). Change in Pain from Pre-Treatment and Comparison Between Groups Evaluated Using Independent t-tests
Pain Diary Data (NRS)
Timepoint

Active

Placebo

Mean 95% CI

P-value

Pre-treatment
0.5 hours

5.40 (±1.50)
4.99 (±1.39)

5.22 (±2.14)
4.98 (±2.13)

0.18 (−0.133 to 0.483)
0.01 (−0.292 to 0.299)

0.26
0.98

2 hours

4.04 (±1.45)

4.61 (±2.08)

−0.57 (−0.865 to −0.265)

<0.001

4 hours

3.24 (±1.61)

4.34 (±2.26)

−1.10 (−1.42 to −0.764)

<0.001

NRS mean change from pre-treatment 95% CI
0.5 hours

−0.416 ±0.724
−0.599 to −0.218
p<0.001

−0.237 ±0.761
−0.713 to 0.239
p=0.328

−0.179 (−0.416 to −0.237)

0.008

2 hours

−1.36 ±1.14
−1.55 to −1.16

−0.615 ±0.962
−1.09 to −0.145

−0.747 (−1.362 to −0.615)

<0.001

p<0.001

p=0.01

−2.16 ±1.56

−0.885 ±0.928

−1.28 (−2.16 to −0.885)

<0.001

−2.36 to −1.95
p<0.001

−1.37 to −0.394
p<0.001

4 hours
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p<0.001). Improved pain relief was noted at all follow-up time
points beginning at the 1st week.

The Global Rate of Change Assessment
Overall, GROC was signiﬁcantly greater in the active
group at 2.84 ± 2.21 points compared to the placebo
group, 0.46 ± 2.08 points (p<0.001). This signiﬁcant difference is apparent for all weeks during the 4-week study,
indicating the active LICUS group considered their overall
health improved signiﬁcantly more than the placebo group
(Table 4).

Discussion
Low-Intensity Continuous Ultrasound (LICUS) is believed
to inactivate myofascial trigger points by increasing tissue
temperature,34 improving local blood ﬂow,54–56 and
increasing tissue extensibility.36,37 Previous studies have
shown a temperature increase of 4 °C up to 3 cm deep in
living human muscle tissue.33 A limitation of our study is
that we did not directly measure trigger point molecular
features or markers but instead determined the clinical
effectiveness and patient satisfaction of LICUS at decreasing the participants’ pain and improving GROC.
A signiﬁcant decrease in pain from baseline was observed
in the active LICUS group at 4 weeks (−2.61 points,
p<0.001). It should be noted that a trend in change from
baseline in the placebo group was observed at 4 weeks and
can probably be attributed to the placebo effect (−1.58
points, p=0.087). Regardless of the placebo effect, the
change in pain reduction of the active LICUS group was
signiﬁcantly greater than the placebo group every week of
the study, including the ﬁnal week (week 4) of treatment.
Low-intensity ultrasound has been approved for bone
healing, considering its mechanotransductive properties
leading to bone regeneration. Ultrasound devices that deliver
pulsed low-intensity ultrasound (0.03W/cm2,1.5MHz, 20%
duty cycle for 20 min, 700 Joules per treatment) for bone

healing provide little thermal effect.30 Additionally, nonthermal, low-energy, pulsed low-intensity ultrasound treatments show non-signiﬁcant clinical effects soft-tissue
tendinopathy,57 shoulder pathology,17,58 and myofascial trigger point pain.17,59 On the other end of the energy delivery
spectrum, LICUS (0.132W/cm2, 3MHz, 100% duty cycle for
4 hrs, 18,720 Joules per treatment) provides mechanotransducive stimulation leading to tissue regeneration, the continuous nature of ultrasound signal provides increased localized
temperature33,34 of the tissue enhancing blood35 and nutrient
ﬂow, oxygenation as well as reduction of inﬂammatory
cytokines.22,31 The LICUS treatment creates a 4°C heating
increase in approximately 80 minutes when factoring for
physiological cooling with participants at rest for multiple
hours.33 Additionally, this 4°C heating change using the
LICUS is maintained over the remaining treatment time.33
Increase tissue temperature has been shown to increase localized blood ﬂow, tissue oxygenation, and reduced level of
inﬂammatory cytokines, as well as the effects are maintained
over for 20 mins post-treatment.33,55,60 We did not measure
the acute effects of the treatment of myofascial trigger points
such as allodynia, range of motion, or thermal effect, but
future research could examine these effects.
LICUS treatment of myofascial trigger points and upper
neck and shoulder pain was explored by Lewis et al (2013).19
The placebo-controlled study applied LICUS from one ultrasound transducer for one hour at 1,584 Joules of energy
delivered per treatment. Lewis et al (2013) observed
a signiﬁcant pain reduction over placebo on the ﬁrst two
days of treatment (active mean 21.25% ± 9%, placebo
mean 4% ± 9%, p<0.05), and mean pain reduction for the
entire 10 days of the study (active mean 16% ± 7%, placebo
8%± 7%) which was only signiﬁcant for male participants
p=0.02.19 In this research study, participants self-applied
LICUS for 4 hours per treatment delivering 18,720 Joules
(12 times more energy than Lewis et al (2013). Participants in
our study had signiﬁcant pain reduction over placebo during

Table 4 The Global Rate of Change Score Reported After (4 hours) of Treatment with SAM. The Comparison Between Groups was
Evaluated Using Independent t-tests
Global Rating of Change
Time

Active

n

Placebo

n

Mean 95% CI

P-value

Week 1

2.35 ±1.96

131

0.76 ±1.89

41

1.59 (0.903 to 2.28)

<0.001

Week 2

2.84 ±2.01

117

0.53 ±2.44

43

2.31 (1.56 to 3.06)

<0.001

Week 3
Week 4

3.21 ±2.45)
3.09 ±2.37)

107
96

0.36 ±1.99
0.14 ±1.93

45
35

2.85 (2.03 to 3.67)
2.95 (2.07 to 3.83)

<0.001
<0.001

Overall

2.84 ±2.21

451

0.46 ±2.08

164

2.38 (1.99 to 2.77)

<0.001
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all weeks of the study, with the greatest pain reduction
occurring in week 4 (NRS −2.61±1.63 points, p<0.001).
Myofascial trigger points are classiﬁed as active and
latent. Active trigger points are generally always tender to
cause pain for the patient, and directly respond to mechanical compression stimulus activating a top neuronal imbalance and segmental muscle dysfunction in the trigger
points reference zone. Latent trigger points are clinically
quiescent with respect to spontaneous pain, and are painful
only when mechanically activated. Latent trigger points
occur because of an ischemic condition creating
a reduction, a decrease in tissue pH, and stimulation of
local nociceptors.8,9,12 Clinically both trigger points are
associated with signiﬁcant pain and loss of function for
patients, and treatments that induce central modulation of
pain, stimulating serotonin release, and enkephalin regulation, may play a role in decreasing myofascial trigger point
pain.10,61 Ultrasound’s ability to alter segmental neural
activity is unknown, and its mechanotransductive effects
may have a positive impact on neural activity associated
with the local tissue healing and regeneration from LICUS
treatment.
Low-intensity continuous ultrasound treatment has the
potential to reduce healthcare costs for both patients and
the healthcare system for the treatment of chronic pain
conditions. Opioids and NSAIDs can cost patients over
$250 per month for similar pain relief to what was found
using a LICUS device.4,5 However, opioids and NSAIDs
can have severe side effects on the neural, gastrointestinal,
and cardiovascular system, requiring additional medication. Dry Needling is a nonpharmacological treatment for
trigger point pain that has also shown similar pain relief to
pharmaceuticals (2.1 to 2.6 point reduction).62 The cost of
dry needling is approximately $100 per treatment session,
and causes minor bleeding or bruising in 5–8% of treatments. Dry needling is generally safe; however, it does
pierce the skin and can pose a small risk to infection.63 To
help manage chronic pain, 3–6 sessions with 10–20 needles may be required. However, there are currently no
clear dosing guidelines for this emerging treatment
option.64 Long-duration continuous ultrasound does not
have any reported adverse reactions being highly local
and non-invasive therapy; there was 100% patient compliance and no reportable side effects across all treatments
self-administered by the participants. Additionally, prescription costs are only a fraction (around 14%) of the
total expenditure for chronic pain conditions.4 The remainder of the cost is associated with imaging, and outpatient
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visits, with some research suggesting 18.8 outpatient visits
on average per patient. The result is a total cost of over
$31,000 per year, which puts a large ﬁnancial burden on
the healthcare system.4
In comparison, the device used here costs $6,800 in
this study and $180/month for one-time use coupling
patches if treating daily. The annual cost would be
$8,960 if patients treated daily. However, this study
found that device use was around three times per week,
reducing the total cost to approximately $7,800 for the
ﬁrst year and $1,000 for the years following. The number
of outpatient visits should also decrease substantially, as
there are no adverse reactions to report or monitor. LICUS
could reduce the overall economic burden on both patients
and the healthcare system while providing safe and effective pain relief for eliminating conditions such as upper
back, neck, and shoulder pain.
The current study focused on the application of LICUS as
a standalone treatment for upper trapezius myofascial pain
relative to the placebo group. Future studies could compare
active LICUS to pharmaceutical options, as well as dry needling and trigger point injections. This study focused primarily
on patient-rated clinical outcomes and did not investigate
acute tissue changes. While the mechanism of action, including increased blood ﬂow, nutrient transfer, mechanical
strength,20,32 myoregeneration,32 and thermal effects,33 probably remain true here and impact clinical outcomes, they were
not speciﬁcally investigated within the scope of this study.
Future research should continue to identify which
pathologies LICUS is most effective for and what are its
physiological effects. In addition, many myofascial pain
conditions are chronic; therefore, future studies should
examine the effectiveness and safety over a longer period
of use. This evidence is encouraging the development and
use of non-drug and non-surgical options to accelerate
biological healing and reduce pain naturally.

Conclusion
LICUS delivery of 18,720 Joules per treatment was successful at treating related pain symptoms of upper trapezius myofascial trigger points relative to the placebo
group. The reduction in pain seen in the active ultrasound
group is clinically signiﬁcant, indicating the wearable
ultrasound device is a possible home-use treatment option
with several advantages over prescription pain medication,
invasive options, and opioids. LICUS provides an attractive home-use treatment option for patients suffering from
upper trapezius myofascial pain.
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